Metabolism Assays Market

Metabolism Assays Market Size, Share & Trends

The global metabolism assays market, valued at US$1.3 billion in 2022, is forecasted to grow at a robust CAGR of 7.8%, reaching US$1.4 billion in 2023 and an impressive US$2.1 billion by 2028. The comprehensive research encompasses an exhaustive examination of industry trends, meticulous pricing analysis, patent scrutiny, insights derived from conferences and webinars, identification of key stakeholders, and a nuanced understanding of market purchasing dynamics.

The growth in this market is attributed to the growing prevalence of diabetes, the global increase in the number of hospitals, and the high rate of obese population. However, alternative methods or techniques restrain the growth of this market.

Metabolism Assays Market Trends

To know about the assumptions considered for the study, Request for Free Sample Report

Metabolism Assays Market Dynamics

DRIVER: Increasing funding and investments in metabolic research

Metabolic research funding and investments are crucial for advancing the metabolic processes understanding, producing new metabolic disease treatments, and improving public health. Diseases like diabetes, obesity, lipid metabolism, mitochondrial disorders, and metabolic pathways are being considered as metabolic diseases. Various sources, including government agencies, private foundations, pharmaceutical companies, and academic institutions are the sources for funding. For instance, clinical-stage biotechnology firm Eccogene raised USD 25.23m (CNY180m) in a Series B financing round to support the development of its clinical-stage metabolic pipeline, in June 2023.

RESTRAINT: High cost of metabolism assay analyzers

The adoption of metabolism assays can be hindered due to the high costs, especially with limited budgeted facilities like smaller research laboratories or healthcare facilities. To mitigate these costs, the organizations may explore options like group purchasing, leasing or financing agreements, and collaborations with larger institutions. There is the development of more cost-effective analyzers or alternative testing methods that reduce expenses while maintaining accuracy and reliability, as technology advances and competition increases. For instance, the Seahorse Xfe 96 Cell Analyzer System and Seahorse XF HS Mini Analyzer by Agilent Technologies, Inc. (US) cost USD 189,612 and USD 68,611, respectively.

OPPORTUNITY: Integration with wearable devices

The overall health monitoring and management experience for individuals can be enhanced by integrating metabolism assay data with digital health platforms, apps, and wearable devices. For instance, Sweat-based wearable technologies have great potential to collect important data on biomarkers which are related to metabolic syndrome and its associated diseases. These wearable devices can measure glucose, CRP, cortisol, and sodium levels, making them invaluable for patients at risk of developing diabetes and cardiovascular diseases.

CHALLENGE: Complexity of assay development

Due to the intricate nature of metabolic pathways and the need for precise measurement techniques, it can be complex and time-consuming to develop accurate and reliable metabolism assays. Ensuring consistency and reproducibility across different experiments and laboratories can be a challenge. A multidisciplinary approach is required for these complexities which involves expertise in biochemistry, cell biology, molecular biology, analytical chemistry, and computational biology.

Metabolism Assays Market Ecosystem

Prominent companies in this market include well-established, financially stable manufacturers of metabolism assays. These companies have been operating in the market for several years and possess diversified state-of-the-art technologies, strong global sales and product portfolios, and marketing networks. Prominent companies in this market include Merck KGaA (Germany), Thermo Fisher (US), Abcam Plc. (UK), and Agilent Technologies Inc. (US).

In 2022, assay kits & reagents segment to observe the highest growth rate of the metabolism assays industry, by product.

Based on product, the metabolism assays market is classified into instruments & analyzers and assay kits & reagents. In 2022, the assay kits & reagents segment dominated the products market. This segment is also estimated to grow at the highest CAGR during the forecast period. The large share can be attributed to features like availability and integration with other technologies like wearable devices.

In 2022, colorimetry segment to dominate the metabolism assays industry, by technology.

Based on technology, the metabolism assays market is segmented into colorimetry, fluorimetry, and spectrometry. The colorimetry segment accounted for the largest share of the market in 2022. Also, this segment is estimated to witness the highest growth during the forecast period. The large share is due to well-established method for measuring metabolites and biomarkers in a wide range of biological samples and large use in industrial settings to assess metabolic parameters and provide valuable data for various applications, including disease diagnosis and drug development.

In 2022, North America to dominate in metabolism assays industry.

The global metabolism assays market is segmented into North America, Europe, Asia Pacific, and Rest of the World. North America is expected to dominate during the forecast period, primarily due to the sedentary work life which will lead to obesity & diabetes, and large population consuming junk food causing obesity. However, during the forecast period, Asia Pacific is expected to register highest CAGR. The factors contributing to the growth of Asia Pacific are large patient pool, growing number of local players, increasing awareness, and rise in disease research fundings by the government.

To know about the assumptions considered for the study, download the pdf brochure

The metabolism assays market is dominated by players such as Merck KGaA (Germany), Thermo Fisher (US), Abcam Plc. (UK), and Agilent Technologies Inc. (US).

Scope of the Metabolism Assays Industry:

This research report categorizes the Metabolism assays market to forecast revenue and analyze trends in each of the following submarkets:

By Region

• North America
• Europe
• Asia Pacific
• Rest of the World

By Product

• Instruments & Analyzers
• Assay Kits & Reagents

By Technology

• Colorimetry
• Fluorimetry
• Spectrometry

By Application

• Diagnostics
• Research

By End User

• Hospitals
• Diagnostics Laboratories
• Pharmaceutical & Biotechnology Companies and CROs & Academic Research Institutes  

Recent Developments of Metabolism Assays Industry:

• In 2022, Thermo Fisher Scientific, Inc. (US) collaborated with Symphogen (Denmark) and Servier (France) for biopharmaceutical discovery and development laboratories.
• In 2021, Abcam Plc. (UK) acquired BioVision (UK). This acquisition of BioVision represents a compelling strategic fit for Abcam. This will bring greater control over the innovation and distribution of BioVision’s product portfolio and create value through portfolio expansion and leveraging Abcam’s global channels to market.
• In 2021, Agilent Technologies Inc. (US) launched Agilent Seahorse XF HS Miniplate which is the latest addition to Agilent’s range of Seahorse XF platforms, which analyze mitochondrial respiration, glycolysis, and ATP production in live cells, in real-time.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst